HERON THERAPEUTICS ($HRTX) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.02 per share, beating estimates of -$0.02 by $0.00. The company also reported revenue of $40,590,000, beating estimates of $40,323,996 by $266,004.
You can see Quiver Quantitative's $HRTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HERON THERAPEUTICS Hedge Fund Activity
We have seen 79 institutional investors add shares of HERON THERAPEUTICS stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 6,921,405 shares (+2785.2%) to their portfolio in Q4 2025, for an estimated $8,997,826
- BAKER BROS. ADVISORS LP removed 4,251,951 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,527,536
- AIGH CAPITAL MANAGEMENT LLC removed 3,009,257 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,791,663
- TANG CAPITAL MANAGEMENT LLC added 2,800,000 shares (+81.2%) to their portfolio in Q4 2025, for an estimated $3,640,000
- CLEARLINE CAPITAL LP added 2,522,712 shares (+26.0%) to their portfolio in Q4 2025, for an estimated $3,279,525
- CITIGROUP INC removed 2,473,051 shares (-99.9%) from their portfolio in Q4 2025, for an estimated $3,214,966
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,387,225 shares (+30.4%) to their portfolio in Q3 2025, for an estimated $3,007,903
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HERON THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $HRTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
To track analyst ratings and price targets for HERON THERAPEUTICS, check out Quiver Quantitative's $HRTX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
